MCID: SCL017
MIFTS: 39

Sclerosing Hemangioma

Categories: Cancer diseases

Aliases & Classifications for Sclerosing Hemangioma

MalaCards integrated aliases for Sclerosing Hemangioma:

Name: Sclerosing Hemangioma 12 14 69
Cutaneous Fibrous Histiocytoma 69
Sclerosing Haemangioma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:495
SNOMED-CT 64 134302009 72079004
UMLS 69 C1509148

Summaries for Sclerosing Hemangioma

MalaCards based summary : Sclerosing Hemangioma, also known as cutaneous fibrous histiocytoma, is related to papilloma and glomangioma. An important gene associated with Sclerosing Hemangioma is NKX2-1 (NK2 Homeobox 1), and among its related pathways/superpathways are Arf6 trafficking events and Cell adhesion_Cadherin-mediated cell adhesion. The drugs Doxorubicin and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include lung, skin and bone.

Wikipedia : 72 Benign fibrous histiocytomas (also known as dermal dendrocytoma,dermatofibroma,fibrous... more...

Related Diseases for Sclerosing Hemangioma

Diseases related to Sclerosing Hemangioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 215)
id Related Disease Score Top Affiliating Genes
1 papilloma 30.1 CTNNB1 MUC1
2 glomangioma 29.5 ENO2 SYP
3 cavernous hemangioma 29.1 CHGA ENO2 SYP
4 lung cancer 26.8 CHGA CTNNB1 CTNND1 ENO2 NKX2-1 SYP
5 pulmonary sclerosing hemangioma 12.2
6 fibrous histiocytoma 11.3
7 hemangioma 10.7
8 chronic neutrophilic leukemia 10.7 MUC1 NKX2-1
9 persian gulf syndrome 10.7 MUC1 NKX2-1
10 pyoderma 10.7 CHGA MUC1
11 epithelioid sarcoma 10.6 MUC1 SYP
12 anaplastic oligodendroglioma 10.6 MUC1 SYP
13 malignant ovarian mixed epithelial neoplasm 10.6 CHGA SYP
14 spinal cord ependymoma 10.6 CHGA SYP
15 ludwig's angina 10.6 CHGA SYP
16 tabes dorsalis 10.6 MUC1 SYP
17 mesenchymoma 10.6 CHGA MUC1
18 signet ring cell intrahepatic cholangiocarcinoma 10.6 CHGA SYP
19 basophilic carcinoma 10.6 CHGA SYP
20 neurogenic thoracic outlet syndrome 10.6 CHGA SYP
21 sebaceous adenoma 10.6 MUC1 SYP
22 aicardi-goutieres syndrome 10.6 CHGA SYP
23 diffuse infiltrative lymphocytosis syndrome 10.6 CHGA SYP
24 diffuse lipomatosis 10.6 CHGA SYP
25 pancreatic ductal carcinoma 10.6 MUC1 SYP
26 thyroid sarcoma 10.6 CHGA SYP
27 superior mesenteric artery syndrome 10.6 NKX2-1 SYP
28 rete ovarii cystadenofibroma 10.6 CHGA SYP
29 perianal skin paget's disease 10.5 CHGA SYP
30 hepatorenal syndrome 10.5 CHGA SYP
31 chondroblastoma 10.5 MUC1 NKX2-1
32 tricuspid valve insufficiency 10.5 CHGA SYP
33 gastroesophageal junction adenocarcinoma 10.5 AR MUC1
34 brain stem ependymoma 10.5 CHGA SYP
35 kidney benign neoplasm 10.5 MUC1 NKX2-1
36 sarcomatoid mesothelioma 10.5 CTNND1 MUC1
37 osteoarthritis 10.5 NKX2-1 SFTPB
38 gliofibroma 10.5 CHGA SYP
39 bone development disease 10.5 NKX2-1 SYP
40 pemphigus vulgaris, familial 10.5 AR MUC1
41 bladder cancer, childhood 10.5 CHGA SYP
42 cecum adenocarcinoma 10.5 MUC1 NKX2-1
43 ureter adenocarcinoma 10.4 CHGA MUC1
44 volkmann contracture 10.4 CHGA SYP
45 periosteal osteogenic sarcoma 10.4 CTNNB1 NKX2-1
46 condrodisplasia punctata rizomélica 10.4 AR MUC1
47 fallopian tube papillary adenocarcinoma 10.4 CHGA SYP
48 breast sarcoma 10.4 CTNNB1 MUC1
49 pleural empyema 10.3 MUC1 NKX2-1 SYP
50 mixed type thymoma 10.3 MUC1 NKX2-1 SYP

Graphical network of the top 20 diseases related to Sclerosing Hemangioma:



Diseases related to Sclerosing Hemangioma

Symptoms & Phenotypes for Sclerosing Hemangioma

Drugs & Therapeutics for Sclerosing Hemangioma

Drugs for Sclerosing Hemangioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 105)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
2
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
3
Mechlorethamine Approved Phase 3,Phase 2,Phase 1 51-75-2 4033
4
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
5
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
6
Dactinomycin Approved Phase 3 50-76-0 2019 457193
7
Epirubicin Approved Phase 3 56420-45-2 41867
8
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
9
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
10
Lenograstim Approved Phase 3,Phase 2 135968-09-1
11
Trabectedin Approved, Investigational Phase 2, Phase 3 114899-77-3 108150
12
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
13 Alkylating Agents Phase 3,Phase 2,Phase 1
14 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
15 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
16 Isophosphamide mustard Phase 3,Phase 2,Phase 1
17 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
18 Anti-Infective Agents Phase 3,Phase 2,Phase 1
19 Antimitotic Agents Phase 3,Phase 2,Phase 1
20 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
21 Antirheumatic Agents Phase 3,Phase 2,Phase 1
22 Etoposide phosphate Phase 3,Phase 2
23 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
24 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
25
Indinavir Approved Phase 2 150378-17-9 5362440
26
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
27
Dacarbazine Approved, Investigational Phase 2 4342-03-4 5351166
28
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
29
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
30
Bevacizumab Approved, Investigational Phase 2 216974-75-3
31
Gemcitabine Approved Phase 2,Phase 1 95058-81-4 60750
32
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
33
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
34
Everolimus Approved Phase 1, Phase 2 159351-69-6 6442177
35
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
36
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030 46835353
37
nivolumab Approved Phase 2,Phase 1 946414-94-4
38
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
39
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
40
Paclitaxel Approved, Vet_approved Phase 1, Phase 2 33069-62-4 36314
41
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4
42
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
43
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
44
Nicotinamide Approved, Nutraceutical Phase 2 98-92-0 936
45
leucovorin Approved, Nutraceutical Phase 2 58-05-9 143 6006
46
Docetaxel Approved May 1996, Investigational Phase 2,Phase 1 114977-28-5 148124 9877265
47
Saracatinib Investigational Phase 2 379231-04-6
48 Soblidotin Investigational Phase 2 149606-27-9
49
Camptothecin Experimental Phase 2 7689-03-4
50 Exatecan Investigational Phase 2 171335-80-1

Interventional clinical trials:

(show top 50) (show all 65)

id Name Status NCT ID Phase Drugs
1 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
2 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
3 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
4 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
5 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
6 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
7 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
8 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
9 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
10 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Recruiting NCT02180867 Phase 2, Phase 3 Doxorubicin Hydrochloride;Ifosfamide;Pazopanib Hydrochloride
11 Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma Recruiting NCT01344018 Phase 3
12 Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma Active, not recruiting NCT00423618 Phase 3
13 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
14 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
15 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
16 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
17 Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma Completed NCT00031915 Phase 2 imatinib mesylate
18 Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma Completed NCT00400569 Phase 2 Sunitinib Malate (SU011248)
19 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
20 Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes Completed NCT00887809 Phase 2 gemcitabine;docetaxel;bevacizumab
21 Bevacizumab and Radiation Therapy for Sarcomas Completed NCT00356031 Phase 2 Bevacizumab
22 Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung Completed NCT00503295 Phase 2
23 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
24 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2 sorafenib tosylate
25 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed NCT00112463 Phase 2 romidepsin
26 Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans or Giant Cell Fibroblastoma Completed NCT00085475 Phase 2 imatinib mesylate
27 Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00064220 Phase 2 soblidotin
28 Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma Completed NCT00949325 Phase 1, Phase 2 temsirolimus (Torisel) plus liposomal doxorubicin (Doxil)
29 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2 BI 2536
30 Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2 perifosine
31 Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00041249 Phase 2 brostallicin
32 Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00041236 Phase 2 exatecan mesylate
33 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
34 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2 trabectedin
35 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
36 Study of Neoadjuvant Checkpoint Blockade in Patients With Surgically Resectable Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma Recruiting NCT03307616 Phase 2 Nivolumab;Ipilimumab
37 Autologous Dendritic Cell Vaccine Loaded With Allogeneic Tumor Lysate Expression of Cancer Testis Antigens in Patients With Soft Tissue Sarcoma Recruiting NCT01883518 Phase 1, Phase 2
38 Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery Recruiting NCT02500797 Phase 2
39 Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma Recruiting NCT03190174 Phase 1, Phase 2 Nab-Rapamycin
40 Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Recruiting NCT02584309 Phase 2 Dexrazoxane;Doxorubicin;Olaratumab
41 Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma Recruiting NCT01532687 Phase 2 Gemcitabine Hydrochloride;Pazopanib Hydrochloride
42 A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma Active, not recruiting NCT00667342 Phase 2 Cisplatin;Doxorubicin;Methotrexate;Ifosfamide;etoposide
43 To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors Active, not recruiting NCT01962103 Phase 1, Phase 2 nab-paclitaxel
44 Alisertib in Treating Patients With Advanced or Metastatic Sarcoma Active, not recruiting NCT01653028 Phase 2 Alisertib
45 Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma Not yet recruiting NCT03123276 Phase 1, Phase 2 Pembrolizumab;Gemcitabine
46 Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery Suspended NCT02923778 Phase 2
47 Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma Suspended NCT02601209 Phase 1, Phase 2 Pazopanib Hydrochloride;Sapanisertib
48 Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) Terminated NCT01418001 Phase 1, Phase 2 Gemcitabine and Docetaxel in Combination with Pazopanib
49 Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Stage IB, Stage II, or Stage III Soft Tissue Sarcoma Terminated NCT00740597 Phase 2
50 Celecoxib and Radiation Therapy in Treating Patients With Stage II or Stage III Soft Tissue Sarcoma of the Arm, Hand, Leg, or Foot That Has Been Removed by Surgery Completed NCT00450736 Phase 1 celecoxib

Search NIH Clinical Center for Sclerosing Hemangioma

Genetic Tests for Sclerosing Hemangioma

Anatomical Context for Sclerosing Hemangioma

MalaCards organs/tissues related to Sclerosing Hemangioma:

39
Lung, Skin, Bone, Liver, Endothelial, Lymph Node, Thyroid

Publications for Sclerosing Hemangioma

Articles related to Sclerosing Hemangioma:

(show top 50) (show all 169)
id Title Authors Year
1
Pneumocytoma (sclerosing hemangioma), a potential pitfall. ( 28398699 )
2017
2
Pulmonary sclerosing hemangioma with a rare symptom: A case report and review of the literature. ( 28357098 )
2017
3
Sclerosing hemangioma of the lung showing strong FDG avidity on PET scan: Case report and review of the current literature. ( 27222778 )
2016
4
Ectopic ACTH syndrome caused by pulmonary carcinoid tumor mimicking long-standing sclerosing hemangioma. ( 26828249 )
2016
5
Co-occurrence of bronchial papilloma and pulmonary sclerosing hemangioma in a male. ( 27812454 )
2016
6
Preoperative Diagnosis in 46 Cases of Pulmonary Sclerosing Hemangioma. ( 27231179 )
2016
7
Pulmonary Hilar Tumor: An Unusual Presentation of Sclerosing Hemangioma. ( 27761142 )
2016
8
Sclerosing hemangioma: A diagnostic dilemma in fine needle aspiration cytology. ( 27168758 )
2016
9
Whole-exome sequencing identifies recurrent AKT1 mutations in sclerosing hemangioma of lung. ( 27601661 )
2016
10
Clinical case report: Sclerosing hemangioma of the liver, a rare but great mimicker. ( 27257450 )
2016
11
Multiple hepatic sclerosing hemangioma mimicking metastatic liver tumor successfully treated by laparoscopic surgery: Report of a case. ( 25679307 )
2015
12
Bone metastasis in pulmonary sclerosing hemangioma. ( 26552471 )
2015
13
Incidental finding of a sclerosing hemangioma in a Caucasian woman. ( 26193226 )
2015
14
Sclerosing hemangioma of the lung. ( 26223076 )
2015
15
Sclerosing Hemangioma of the Lung Mimicking Pulmonary Metastasis. ( 25762452 )
2015
16
Pulmonary sclerosing hemangioma with lymph node metastasis: A case report and literature review. ( 24944657 )
2014
17
The significance of p40 expression in sclerosing hemangioma of lung. ( 25130377 )
2014
18
Histogenesis of pulmonary sclerosing hemangioma and significance of P63 expression. ( 23910931 )
2013
19
Pneumocytoma (formerly known as sclerosing hemangioma of the lung): a rare cause of chest pain. ( 23380035 )
2013
20
Pulmonary sclerosing hemangioma: a unique epithelial neoplasm of the lung (report of 26 cases). ( 23587094 )
2013
21
A hepatic sclerosed hemangioma with significant morphological change over a period of 10 years: a case report. ( 23714181 )
2013
22
Cytologic features of sclerosing hemangioma of the lung on crush preparations. ( 21710650 )
2013
23
A sclerosing hemangioma of the liver. ( 24459649 )
2013
24
A rare tumor of the lung: pulmonary sclerosing hemangioma (pneumocytoma). ( 23290153 )
2013
25
Synchronous occurrence of breast cancer and pulmonary sclerosing hemangioma: management and review of the literature. ( 23838116 )
2013
26
Unusual coexistence of pulmonary sclerosing hemangioma and pericardial cyst. ( 24887810 )
2013
27
Diagnosis of sclerosing hemangioma of lung: don't rely on fine-needle aspiration cytology diagnosis alone. ( 24518736 )
2013
28
18F-FDG PET/CT features of pulmonary sclerosing hemangioma. ( 22291338 )
2013
29
Sclerosing hemangioma of the lung manifesting as a cystic lesion with an air-fluid level. ( 22832056 )
2012
30
Napsin A is differentially expressed in sclerosing hemangiomas of the lung. ( 23194051 )
2012
31
Fine-needle aspiration diagnosis of sclerosing hemangioma (pneumocytoma): Report of a case and review of the literature. ( 22645055 )
2012
32
A case of pulmonary sclerosing hemangioma with low (18)FDG uptake in PET. ( 22740968 )
2012
33
Treatment of 28 patients with sclerosing hemangioma (SH) of the lung. ( 22515818 )
2012
34
In pulmonary sclerosing hemangioma expression of I^-catenin, Axin, and C-myc differs between the two cell types. ( 22614067 )
2012
35
Pulmonary sclerosing hemangioma presenting with dense spindle stroma cells: a potential diagnostic pitfall. ( 23227905 )
2012
36
Pulmonary sclerosing hemangioma: report of two cases. ( 22943472 )
2012
37
A case of sclerosing hemangioma forming a pedunculated mass. ( 21881332 )
2011
38
Sclerosing hemangioma in the liver. ( 22102394 )
2011
39
Pulmonary sclerosing hemangioma with pleural dissemination: report of a case. ( 21264765 )
2011
40
Microscopic sclerosing hemangioma diagnosed by histopathological examination after lung cancer surgery. ( 21881377 )
2011
41
Pulmonary sclerosing hemangioma: pitfalls in management. ( 21471259 )
2011
42
Pulmonary sclerosing hemangioma in a 21-year-old male with metastatic hereditary non-polyposis colorectal cancer: report of a case. ( 21645337 )
2011
43
A case of pulmonary sclerosing hemangioma surrounded by giant cystic change on high-resolution computed tomography. ( 20634757 )
2011
44
F-18 FDG PET/CT in evaluation of pulmonary sclerosing hemangioma. ( 21467848 )
2011
45
Coexistence of pulmonary sclerosing hemangioma and primary adenocarcinoma in the same nodule of lung. ( 21599956 )
2011
46
Determination of clonal status of pulmonary sclerosing hemangioma with X-chromosome inactivation mosaicism and polymorphism of phosphoglycerate kinase and androgen receptor genes. ( 20422318 )
2011
47
Comparison of genetic and epigenetic alterations at 11 tumor suppressor loci in pulmonary sclerosing hemangioma and adenocarcinoma. ( 21649526 )
2011
48
Surgery for Pulmonary Sclerosing Hemangioma: Lobectomy versus Limited Resection. ( 22263122 )
2011
49
Multiple FDG-avid sclerosing hemangiomas mimicking pulmonary metastases in a case of soft tissue sarcoma. ( 20675249 )
2010
50
So-called sclerosing hemangioma of lung: current concept. ( 20123460 )
2010

Variations for Sclerosing Hemangioma

Expression for Sclerosing Hemangioma

Search GEO for disease gene expression data for Sclerosing Hemangioma.

Pathways for Sclerosing Hemangioma

GO Terms for Sclerosing Hemangioma

Biological processes related to Sclerosing Hemangioma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 in utero embryonic development GO:0001701 9.58 AR CTNNB1 MUC1
2 androgen receptor signaling pathway GO:0030521 9.46 AR CTNNB1
3 adherens junction organization GO:0034332 9.43 CTNNB1 CTNND1
4 epithelial tube branching involved in lung morphogenesis GO:0060441 9.37 CTNNB1 NKX2-1
5 cellular process GO:0009987 9.32 AR CTNNB1
6 entry of bacterium into host cell GO:0035635 9.26 CTNNB1 CTNND1
7 Leydig cell differentiation GO:0033327 9.16 AR NKX2-1
8 epithelial cell differentiation involved in prostate gland development GO:0060742 8.96 AR CTNNB1
9 positive regulation of epithelial cell proliferation involved in prostate gland development GO:0060769 8.62 AR CTNNB1

Molecular functions related to Sclerosing Hemangioma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 transcription regulatory region DNA binding GO:0044212 8.8 AR CTNNB1 NKX2-1

Sources for Sclerosing Hemangioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....